MedTrace Logo

Changes in mRNA Expression Following Exposure to Naproxen

NCT01090596 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2010-03-22

No results posted yet for this study

Summary

Using tissue samples obtained from a previous study, the effect of naproxen on the gene expression profiles of antral mucosal tissue will be assessed. We hypothesize that there will be distinct changes in the gene expression profiles of samples taken from individuals treated with naproxen versus samples taken from individuals treated with placebo.

Conditions

  • Healthy

Interventions

DRUG

Naproxen

500mg naproxen, twice daily for 7 days

DRUG

Placebo

1 tab,twice a day for a seven days

Sponsors & Collaborators

  • Research Associates of New York, LLP

    lead OTHER

Principal Investigators

  • James Aisenberg, MD · Research Associates of New York

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-06-30
Completion
2008-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01090596 on ClinicalTrials.gov